Alexion Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexion Pharmaceuticals Inc.
Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.
- Large Molecule
- Other Names / Subsidiaries
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- Enobia Pharma Corp.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB